FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311354489> ?p ?o ?g. }

• W4311354489 abstract "Introduction Immune checkpoint inhibitors (ICIs) have shown promising results for the treatment of multiple cancers. ICIs and related therapies may also be useful for the treatment of thyroid cancer (TC). In TC, Myc binding protein 2 (MYCBP2) is correlated with inflammatory cell infiltration and cancer prognosis. However, the relationship between MYCBP2 expression and ICI efficacy in TC patients is unclear. Methods We downloaded data from two TC cohorts, including transcriptomic data and clinical prognosis data. The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm was used to predict the efficacy of ICIs in TC patients. MCPcounter, xCell, and quanTIseq were used to calculate immune cell infiltration scores. Gene set enrichment analysis (GSEA) and single sample GSEA (ssGSEA) were used to evaluate signaling pathway scores. Immunohistochemical (IHC) analysis and clinical follow up was used to identify the MYCBP2 protein expression status in patients and associated with clinical outcome. Results A higher proportion of MYCBP2-high TC patients were predicted ICI responders than MYCBP2-low patients. MYCBP2-high patients also had significantly increased infiltration of CD8+ T cells, cytotoxic lymphocytes (CTLs), B cells, natural killer (NK) cells and dendritic cells (DC)s. Compared with MYCBP2-low patients, MYCBP2-high patients had higher expression of genes associated with B cells, CD8+ T cells, macrophages, plasmacytoid dendritic cells (pDCs), antigen processing and presentation, inflammatory stimulation, and interferon (IFN) responses. GSEA and ssGSEA also showed that MYCBP2-high patients had significantly increased activity of inflammatory factors and signaling pathways associated with immune responses.In addiation, Patients in our local cohort with high MYCBP2 expression always had a better prognosis and greater sensitivity to therapy while compared to patients with low MYCBP2 expression after six months clinic follow up. Conclusions In this study, we found that MYCBP2 may be a predictive biomarker for ICI efficacy in TC patients. High MYCBP2 expression was associated with significantly enriched immune cell infiltration. MYCBP2 may also be involved in the regulation of signaling pathways associated with anti-tumor immune responses or the production of inflammatory factors." @default.
• W4311354489 created "2022-12-25" @default.
• W4311354489 creator A5008627959 @default.
• W4311354489 creator A5011539007 @default.
• W4311354489 creator A5031458620 @default.
• W4311354489 creator A5033068235 @default.
• W4311354489 creator A5037891463 @default.
• W4311354489 creator A5040924420 @default.
• W4311354489 creator A5057308417 @default.
• W4311354489 creator A5074476383 @default.
• W4311354489 creator A5077406682 @default.
• W4311354489 creator A5084948501 @default.
• W4311354489 date "2022-12-13" @default.
• W4311354489 modified "2023-10-17" @default.
• W4311354489 title "MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients" @default.
• W4311354489 cites W1561070512 @default.
• W4311354489 cites W1561349380 @default.
• W4311354489 cites W1851889911 @default.
• W4311354489 cites W1967792499 @default.
• W4311354489 cites W1980568044 @default.
• W4311354489 cites W2008196398 @default.
• W4311354489 cites W2013454062 @default.
• W4311354489 cites W2021880490 @default.
• W4311354489 cites W2029229136 @default.
• W4311354489 cites W2038014733 @default.
• W4311354489 cites W2062718503 @default.
• W4311354489 cites W2086890478 @default.
• W4311354489 cites W2091596054 @default.
• W4311354489 cites W2114843025 @default.
• W4311354489 cites W2119501407 @default.
• W4311354489 cites W2122956665 @default.
• W4311354489 cites W2134582937 @default.
• W4311354489 cites W2135730659 @default.
• W4311354489 cites W2138778951 @default.
• W4311354489 cites W2151834630 @default.
• W4311354489 cites W2156353875 @default.
• W4311354489 cites W2159707944 @default.
• W4311354489 cites W2168076926 @default.
• W4311354489 cites W2273578071 @default.
• W4311354489 cites W2329659234 @default.
• W4311354489 cites W2332521027 @default.
• W4311354489 cites W2336715782 @default.
• W4311354489 cites W2410864298 @default.
• W4311354489 cites W2527905628 @default.
• W4311354489 cites W2533508881 @default.
• W4311354489 cites W2567564314 @default.
• W4311354489 cites W2572174216 @default.
• W4311354489 cites W2603577764 @default.
• W4311354489 cites W2621506639 @default.
• W4311354489 cites W2680122361 @default.
• W4311354489 cites W2744849445 @default.
• W4311354489 cites W2766581537 @default.
• W4311354489 cites W2767034759 @default.
• W4311354489 cites W2783034964 @default.
• W4311354489 cites W2784727484 @default.
• W4311354489 cites W2788178388 @default.
• W4311354489 cites W2809141554 @default.
• W4311354489 cites W2853155820 @default.
• W4311354489 cites W2886498337 @default.
• W4311354489 cites W2887187316 @default.
• W4311354489 cites W2900082702 @default.
• W4311354489 cites W2921457104 @default.
• W4311354489 cites W2946952121 @default.
• W4311354489 cites W2950733633 @default.
• W4311354489 cites W2952001873 @default.
• W4311354489 cites W2990386639 @default.
• W4311354489 cites W2991118872 @default.
• W4311354489 cites W3002618253 @default.
• W4311354489 cites W3036531813 @default.
• W4311354489 cites W3041112897 @default.
• W4311354489 cites W3049406555 @default.
• W4311354489 cites W3049733355 @default.
• W4311354489 cites W3085521743 @default.
• W4311354489 cites W3089064012 @default.
• W4311354489 cites W3093762626 @default.
• W4311354489 cites W3118085702 @default.
• W4311354489 cites W3126772227 @default.
• W4311354489 cites W3128646645 @default.
• W4311354489 cites W3183142599 @default.
• W4311354489 cites W3194506780 @default.
• W4311354489 cites W4225957066 @default.
• W4311354489 cites W3118842452 @default.
• W4311354489 doi "https://doi.org/10.3389/fimmu.2022.1048503" @default.
• W4311354489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36582246" @default.
• W4311354489 hasPublicationYear "2022" @default.
• W4311354489 type Work @default.
• W4311354489 citedByCount "1" @default.
• W4311354489 crossrefType "journal-article" @default.
• W4311354489 hasAuthorship W4311354489A5008627959 @default.
• W4311354489 hasAuthorship W4311354489A5011539007 @default.
• W4311354489 hasAuthorship W4311354489A5031458620 @default.
• W4311354489 hasAuthorship W4311354489A5033068235 @default.
• W4311354489 hasAuthorship W4311354489A5037891463 @default.
• W4311354489 hasAuthorship W4311354489A5040924420 @default.
• W4311354489 hasAuthorship W4311354489A5057308417 @default.
• W4311354489 hasAuthorship W4311354489A5074476383 @default.
• W4311354489 hasAuthorship W4311354489A5077406682 @default.
• W4311354489 hasAuthorship W4311354489A5084948501 @default.
• W4311354489 hasBestOaLocation W43113544891 @default.
• W4311354489 hasConcept C104317684 @default.

• next